Virax Biolabs Group Ltd (VRAX) director discloses multiple option grants

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Virax Biolabs Group Ltd director Norton Evan Michael filed an initial statement of beneficial ownership, reporting stock option holdings over the company’s ordinary shares. He holds options for 2,000 shares at an exercise price of $6.0000 expiring on July 20, 2032, and 10,000 shares at $6.0000 expiring on April 18, 2033. He also holds 10,000 options at $0.6800 expiring on April 18, 2034 and 10,000 options at $0.8800 expiring on April 8, 2035. Footnotes state these options were granted between July 20, 2022 and April 8, 2025 under the company’s equity incentive plans, with vesting in halves or thirds and becoming exercisable upon vesting.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Norton Evan Michael

Role Director

Type	Security	Shares	Price	Value
holding	Stock Options (right to buy)	--	--	--
holding	Stock Options (right to buy)	--	--	--
holding	Stock Options (right to buy)	--	--	--
holding	Stock Options (right to buy)	--	--	--

Holdings After Transaction: Stock Options (right to buy) — 2,000 shares (Direct)

Footnotes (1)

On July 20, 2022, the Company granted 2,000 stock options under the Company's 2023 Equity Incentive Plan. The stock options are fully vested. On April 18, 2023, the Company granted 10,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal halves on April 18 of each of 2024 and 2025. The vested portions of such options will become exercisable upon vesting. On April 18, 2024, the Company granted 10,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2025, 2026 and 2027. The vested portions of such options will become exercisable upon vesting. On April 8, 2025, the Company granted 10,000 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027 and 2028. The vested portions of such options will become exercisable upon vesting.

Understanding Insider Trading Forms →

03/18/2026 - 04:05 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Norton Evan Michael

(Last)

(First)

(Middle)

BIOCITY GLASGOW BO'NESS ROAD

NEWHOUSE LANARKSHIRE

(Street)

MOTHERWELL LANARKSHIRE

UNITED KINGDOM

ML1 5UH

(City)

(State)

(Zip)

UNITED KINGDOM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Virax Biolabs Group Ltd [ VRAX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Options (right to buy)	⁽¹⁾	07/20/2032	Ordinary Shares	2,000	$6	D
Stock Options (right to buy)	⁽²⁾	04/18/2033	Ordinary Shares	10,000	$6	D
Stock Options (right to buy)	⁽³⁾	04/18/2034	Ordinary Shares	10,000	$0.68	D
Stock Options (right to buy)	⁽⁴⁾	04/08/2035	Ordinary Shares	10,000	$0.88	D

Explanation of Responses:

1. On July 20, 2022, the Company granted 2,000 stock options under the Company's 2023 Equity Incentive Plan. The stock options are fully vested.

2. On April 18, 2023, the Company granted 10,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal halves on April 18 of each of 2024 and 2025. The vested portions of such options will become exercisable upon vesting.

3. On April 18, 2024, the Company granted 10,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2025, 2026 and 2027. The vested portions of such options will become exercisable upon vesting.

4. On April 8, 2025, the Company granted 10,000 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027 and 2028. The vested portions of such options will become exercisable upon vesting.

	/s/ Evan Norton	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the Virax Biolabs (VRAX) Form 3 filing show for Norton Evan Michael?

The Form 3 shows Norton Evan Michael’s existing stock option holdings in Virax Biolabs. He reports several option grants over ordinary shares with specific exercise prices, expiration dates, and vesting schedules under the company’s equity incentive plans.

How many Virax Biolabs (VRAX) options does Norton Evan Michael report owning?

Norton Evan Michael reports options over 2,000 ordinary shares at $6.0000, plus three separate 10,000-share option grants. These have exercise prices of $6.0000, $0.6800, and $0.8800, each with its own future expiration date.

What are the exercise prices and expirations of Norton Evan Michael’s VRAX options?

He holds options at $6.0000 expiring on July 20, 2032 and April 18, 2033, at $0.6800 expiring on April 18, 2034, and at $0.8800 expiring on April 8, 2035. All relate to Virax Biolabs ordinary shares.

How do Norton Evan Michael’s Virax Biolabs (VRAX) options vest?

Footnotes state a 2,000-option grant from July 20, 2022 is fully vested. A 10,000 grant from April 18, 2023 vests in halves over 2024 and 2025, while 2024 and 2025 grants each vest in equal thirds over three future years.

Under which plans were Norton Evan Michael’s VRAX options granted?

The Form 3 notes that grants dated July 20, 2022, April 18, 2023, and April 18, 2024 were issued under Virax Biolabs’ 2023 Equity Incentive Plan. The April 8, 2025 grant was issued under the company’s 2024 Equity Incentive Plan.